Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy

Background: Despite advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), primary and secondary resistance to current therapies remains. Elevated circulating sphingolipids are associated with poor outcomes in patients with mCRPC, including therapeutic resistance and s...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Rhiannon Mellor, Luke Ardolino, Tahlia Scheinberg, Michael Fitzpatrick, Hui-Ming Lin, Paul Bonnitcha, David Sullivan, Peter J. Meikle, Martin R. Stockler, Tania Moujaber, Anthony Joshua, Lisa Horvath
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	SAGE Publishing 2024-12-01
Цуврал:	Therapeutic Advances in Medical Oncology
Онлайн хандалт:	https://doi.org/10.1177/17588359241307814
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!